Amiselimod, a novel sphingosine 1‐phosphate receptor‐1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk - Concepedia

Concepedia

Publication | Open Access

Amiselimod, a novel sphingosine 1‐phosphate receptor‐1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk

DOI Full Paper Access

83

Citations

30

References

2016

Year

Kunio Sugahara, Yasuhiro Maeda, Kyoko Shimano, Akira Mogami, Hirotoshi Kataoka, Kei Ogawa, Kumiko Hikida, Hiroshi Kumagai, Mahoko Asayama, Toshinobu Yamamoto,

British Journal of Pharmacology

Abstract

Amiselimod exhibited potent therapeutic efficacy with minimal cardiac effects at the anticipated clinical dose and is unlikely to require dose titration.

References

	Year	Citations

Page 1